The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin

Hormone and Metabolic Research

Volumn 30, Issue 3, 1998, Pages 123-129

  Berti, L ^a   Kellerer, M ^a   Bossenmaier, B ^a   Seffer, E ^a   Seipke, G ^b   Haring H U ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b SANOFI   (France)

Author keywords

Insulin analog; Insulin receptor; Insulin therapy; Long fast acting insulins; Mitogenesis

Indexed keywords

FOCAL ADHESION KINASE; HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN RECEPTOR; INSULIN[B10 ASPARTIC ACID]; THYMIDINE; TRITIUM; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG RECEPTOR BINDING; FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALIA; TRITIUM;

EID: 0031918749     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978849     Document Type: Article

References (24)

1. Eaton RP, Allen RC, Schade DS, Standefer JC. "Normal" insulin secretion: the goal of artificial insulin delivery systems? Diabetes Care 1980; 3: 270-3
2. Rizza RA, Gerich JE, Haymond MW, Westland RE, Hall LD, Clemens AH, Service FJ. Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy. New Engl J Med 1980; 303: 1313-8
3. Home PD, Pickup JC, Keen H, Alberti KGMM, Parsons JA, Binder C. Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or bolus injection of the mealtime dose. Metabolism 1981; 30: 439-42
4. Seipke G, Geisen K, Neubauer HP, Pittius C, Roßkamp R, et al. New insulin preparations with prolonged action profiles. Diabetologia 1992; 35: A4 (Abstract)
5. Dreyer M, Pein M, Schmidt B, Heidtmann B, Schlünzen M, Roßkamp R. Comparison of the pharmacokinetics/dynamics of GLY(A21)-ARG(B31,B32)-human-insulin (HOE71 GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique. Diabetologia 1994; 37 (Suppl. 1): A78
6. Talaulicar M, Willms M, Roßkamp R. Efficacy of HOE 901 following subcutaneous injection for four days in type I diabetic subjects . Diabetologia 1994; 37 (Suppl. 1): A169
7. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Særensen AR, Voigt HO. Monomeric insulins obtained by protein engineering and their medical implications. Nature (Lond) 1988; 333: 679-82
8. Drejer K, Kruse V, Dahl Larsen U, Hougaard P, Særen B, Gammeltoft S. Receptor binding and tyrosine kinase activation by insu lin analogue with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 1991; 40: 1488-95
9. Schwartz GP, Thompson Burke G, Katsoyannis PG. A superactive insulin: [B10-Aspartic acid]insulin(human). Proc Nat Acad Sci USA 1987; 84: 6408-11
10. Bornfeldt KE, Gidlöf RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 1991; 34: 307-13
11. Vincent MT, Carroll RJ, Hammer RE, Chan SJ, Guz Y, Steiner DF, Teitelman G. A transgene coding for a human insulin analog has a mitogenic effect on murine embryonic beta cells. Proc Nat Acad Sci USA 1995; 92: 6239-43
12. Berti L, Mosthaf L, Kroder G, Kellerer M, Tippmer S, Mushack J, Seffer E, Seedorf K, Häring H. Glucose-induced translocation of protein kinase C isoforms in rat-1 fibroblasts is paralleled by inhibition of the insulin receptor tyrosine kinase. J Biol Chem 1994; 269: 3381-6
13. Gliemann J, Gammeltoft S. The biological activity and the binding affinity of modified insulins determined on isolated fat cells. Diabetologia 1974; 10: 105-13
14. White MF, Maron R, Kahn CR. Insulin rapidly stimulates tyrosine phosphorylation of a MG 185000 protein in intact cells. Nature (Lond) 1995; 318: 183-6
15. Meyers MG Jr, Sun XJ, White MF. The IRS-1 signaling system. Trends Biochem Sct 19: 289-93
16. Pillay TS, Sasaoka T, Olefsky JM. Insulin stimulates the tyrosine dephosphorylation of pp125 focal adhesion kinase. J Biol Chem 1995; 270: 991-4
17. Vogt B, Carrascosa JM, Ermel B, Ullrich A, Häring HU. The two isotypes of the human insulin receptor (HIR A and HIR B) follow different internalization kinetics. Biochem Biophys Res Commun 1991; 177: 1013-8
18. Brange J, Owens DR, Rang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-54
19. Kornberg L, Earp HS, Parsons JT, Schaller M, Juliano RL. Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J Biol Chem 1992; 267: 23439-42
20. Zachary I, Sinneth-Smith J, Rozengurt E, Bombesin, vasopressin, and endothelin stimulation of tyrosine phosphorylation in Swiss 3 T3 cells. J Biol Chem 1992; 267: 19031-4
21. FAK and paxillin are substrates for bradykinin-stimulated tyrosine phosphorylation in Swiss 3 T3 cells. J Biol Chem 1994; 269: 24328-34
22. Chen HC, Guan JL. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Nat Acad Sci USA 1994; 91: 10148-52
23. FAK. Mol Cell Biol 1994; 14: 147-55
24. FAK) by a mechanism involving a phosphotyrosine-phosphatase. Diabetologia 1995; 38 (Suppl. 1): A68